All Title Author
Keywords Abstract

PLOS Biology  2007 

Big Pharma (The Play)

DOI: 10.1371/journal.pbio.0050104

Full-Text   Cite this paper   Add to My Lib



[1]  Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) Narrative review: The promotion of Gabapentin: An analysis of internal industry documents. Ann Intern Med 145: 284–293.
[2]  Norris P, Herxheimer A, Lexchin J, Mansfield P (2005) Drug promotion: What we know, what we have yet to learn. Geneva: World Health Organization, Health Action International. Available: Accessed 22 February 2007.
[3]  Roth M (1996) Patterns in direct-to-consumer prescription drug advertising and their policy implications. J Public Policy Mark 15: 63–75.
[4]  Applbaum K (2006) Pharmaceutical marketing and the invention of the medical consumer. PLoS Med 3: e189. doi: 10.1371/journal.pmed.0030189.
[5]  Bowman MA, Pearle DL (1988) Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 8: 13–20.
[6]  Chren MM, Landefeld CS (1994) Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271: 684–689.
[7]  Avorn J, Chen M, Hartley R (1982) Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 73: 4–8.
[8]  Haayer F (1982) Rational prescribing and sources of information. Soc Sci Med 16: 2017–2023.
[9]  Wazana A (2000) Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283: 373–380.
[10]  Steinman MA, Shlipak MG, McPhee SJ (2001) Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 110: 551–557.
[11]  Keim SM, Sanders AB, Witzke DB, Dyne P, Fulginiti JW (1993) Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. Ann Emerg Med 22: 1576–1581.
[12]  Brotzman GL, Mark DH (1993) The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities. J Gen Intern Med 8: 130–134.
[13]  McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS (2001) Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 286: 1994–1999.
[14]  Lipsky M, Taylor C (1997) The opinions and experiences of family physicians regarding direct-to-consumer advertising. J Fam Pract 45: 495–499.
[15]  Gilbody S, Wilson P, Watt I (2005) Benefits and harms of direct to consumer advertising: A systematic review. Qual Saf Health Care 14: 246–250.
[16]  Moynihan R, Cassels A (2005) Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books.
[17]  Moynihan R, Henry D (2006) The fight against disease mongering: Generating knowledge for action. PLoS Med 3: e191. doi: 10.1371/journal.pmed.0030191.
[18]  Bell R, Kravitz R, Wilkes M (1999) Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med 14: 651–657.
[19]  Wilkes M, Bell R, Kravitz R (2000) Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Aff 19: 110–128.


comments powered by Disqus

Contact Us


微信:OALib Journal